Search for content and authors |
Application of amylose tris(3,5dimethylphenyl- carbamate) chiral stationary phase for the determination of paroxetine, clinically used psychotropic drug |
Małgorzata Lisowska Kuźmicz 1, Agnieszka Ocios-Bębenek 1, Małgorzata Kantor-Boruta 1, Anna Jończyk 1, Małgorzata Jarończyk 1, Aleksander P. Mazurek 1,2, Zdzisław Chilmonczyk 1 |
1. Narodowy Instytut Lekow (NIL), Chełmska 30/34, Warszawa 00-725, Poland |
Abstract |
Paroxetine {(-)-(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine]} is a potent, selective serotonin reuptke inhibitor exhibiting minor affinity to muscarinic and cholinergic receptors. In clinics it is mainly used in major depression, anxiety and obsessive-compulsive disorders. In pharmaceutical preparations - beside (-)-trans-paroxetine (I) - (+)-trans-paroxetine, its probably inactive enantiomer [1], may be present. Here we report validated analytical procedure enabling determination of (+/-)-trans-paroxetine in medicinal products containing (+)-trans-paroxetine as a main active ingredient with the aid of amylose tris(3,5dimethylphenylcarbamate) chiral stationary phase. Validation included: specificity, linearity, limit of detection (LOD), limit of quantification (LOQ), assay, precision and recovery. 1. Segura M., Roura L., de la Torre R., Joglar J.; Synthesis of the major metabolites |
Legal notice |
|
Related papers |
Presentation: Poster at VIII Multidyscyplinarna Konferencja Nauki o Leku, by Małgorzata Lisowska KuźmiczSee On-line Journal of VIII Multidyscyplinarna Konferencja Nauki o Leku Submitted: 2012-03-14 10:06 Revised: 2012-05-10 00:27 |